IGC Pharma, Inc.
IGC
$0.3262
$0.01986.46%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.24M | 1.18M | 1.06M | 1.35M | 1.22M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.24M | 1.18M | 1.06M | 1.35M | 1.22M |
| Cost of Revenue | 600.00K | 518.00K | 421.00K | 612.00K | 591.00K |
| Gross Profit | 636.00K | 665.00K | 641.00K | 733.00K | 625.00K |
| SG&A Expenses | 6.05M | 7.15M | 7.50M | 7.48M | 8.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.16M | 11.23M | 11.84M | 11.87M | 12.97M |
| Operating Income | -8.92M | -10.04M | -10.78M | -10.52M | -11.76M |
| Income Before Tax | -8.81M | -12.57M | -13.30M | -13.00M | -14.15M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.81 | -12.57 | -13.30 | -13.00 | -14.15 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.81M | -12.57M | -13.30M | -13.00M | -14.15M |
| EBIT | -8.92M | -10.04M | -10.78M | -10.52M | -11.76M |
| EBITDA | -8.30M | -9.41M | -10.13M | -9.89M | -11.13M |
| EPS Basic | -0.12 | -0.19 | -0.21 | -0.22 | -0.25 |
| Normalized Basic EPS | -0.08 | -0.09 | -0.11 | -0.11 | -0.13 |
| EPS Diluted | -0.12 | -0.19 | -0.21 | -0.22 | -0.25 |
| Normalized Diluted EPS | -0.08 | -0.09 | -0.11 | -0.11 | -0.13 |
| Average Basic Shares Outstanding | 290.70M | 276.79M | 255.08M | 235.35M | 224.17M |
| Average Diluted Shares Outstanding | 290.70M | 276.79M | 255.08M | 235.35M | 224.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
